D. E. Shaw & Co., Inc. - ZENTALIS PHARMACEUTICALS INC ownership

ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 132 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.

Quarter-by-quarter ownership
D. E. Shaw & Co., Inc. ownership history of ZENTALIS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$751,026
+19.0%
37,439
+28.6%
0.00%0.0%
Q3 2022$631,000
-59.0%
29,112
-46.8%
0.00%
-50.0%
Q2 2022$1,538,000
+59.0%
54,745
+161.2%
0.00%
+100.0%
Q1 2022$967,000
-36.4%
20,959
+15.8%
0.00%0.0%
Q4 2021$1,521,000
-58.1%
18,092
-66.8%
0.00%
-66.7%
Q3 2021$3,628,000
+20.8%
54,438
-3.6%
0.00%0.0%
Q2 2021$3,003,000
+212.2%
56,454
+154.6%
0.00%
+200.0%
Q1 2021$962,000
-59.1%
22,171
-51.0%
0.00%
-50.0%
Q4 2020$2,352,000
+801.1%
45,287
+466.6%
0.00%
Q3 2020$261,000
-78.2%
7,993
-67.9%
0.00%
-100.0%
Q2 2020$1,197,00024,9350.00%
Other shareholders
ZENTALIS PHARMACEUTICALS INC shareholders Q1 2022
NameSharesValueWeighting ↓
TYBOURNE CAPITAL MANAGEMENT (HK) LTD 2,426,095$111,940,0006.63%
Paradigm Biocapital Advisors LP 287,577$13,269,0003.51%
Avidity Partners Management LP 3,176,999$146,587,0003.05%
Integral Health Asset Management, LLC 215,000$9,920,0002.58%
Matrix Capital Management Company, LP 4,349,279$200,676,0002.41%
Affinity Asset Advisors, LLC 207,500$9,574,0001.53%
Ikarian Capital, LLC 202,203$9,329,0001.23%
Ghost Tree Capital, LLC 80,000$3,691,0000.80%
Eventide Asset Management 761,000$35,113,0000.55%
Perceptive Advisors 501,509$23,140,0000.46%
View complete list of ZENTALIS PHARMACEUTICALS INC shareholders